Navigation Links
Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Date:3/10/2010

NEW YORK, March 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 22nd Annual ROTH OC Growth Stock Conference, being held in Laguna Niguel, CA. Mr. Bentsur's presentation will take place on Tuesday March 16, 2010 at 8:00 a.m. PT (11:00 am ET).

A live webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

As previously announced, the Company will also be presenting at the Cowen and Company 30th Annual Health Care Conference, taking place at The Boston Marriott Copley Place Hotel in Boston, MA.  A live webcast of Mr. Bentsur's presentation, which will take place tomorrow, Thursday, March 11, 2010 at 11:05 a.m. ET, will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, with a Phase 3 trial in refractory metastatic colorectal cancer, under SPA, pending commencement, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex™ (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx is headquartered in New York City.

Media Contact: Lauren Fischer, Director of Investor Relations, Keryx Biopharmaceuticals, +1-212-531-5962, lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Back to top

RELATED LINKS
http://investors.keryx.com

'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
4. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
5. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
9. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer Ingelheim ... in patients with unresectable malignant pleural mesothelioma (MPM) ... The data, presented at the 17 th ... Vienna , showed nintedanib plus pemetrexed/cisplatin ... plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
(Date:12/7/2016)... 7, 2016  Lannett Company, Inc. (NYSE: LCI ) ... Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 ... New York City . In addition, the ... Guggenheim Securities 4 th Annual Boston Healthcare Conference taking place ... ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated ... Health on Voice of America, declared on her radio program in November 2016 the ... that when these bullies attack leaders in corporate America, they are trying to take ...
(Date:12/7/2016)... ... 2016 , ... 1105 Media’s Live From program has been ... competition. Live From won in the Use of Social Media category. The Folio: ... undertaken by the media industry’s most innovative marketing professionals. , Conceived ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly ... team of three acupuncturists to help patients realize their family building goals. ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... individuals impacted by cerebral cavernous angiomas, was awarded a grant from the Julian ... engagement program. New Mexico has more people with cavernous angioma than anywhere in ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
Breaking Medicine News(10 mins):